Anti-Hypertensive Drugs Market Poised to Expand at a Robust Pace Over 2020-2025 | Novartis, Pfizer, Johnson & Johnson, Sanofi, Lupin, Ranbaxy Laboratories, Merck, AstraZeneca, Takeda

This report provides in-depth study on the current state of the Global Anti-Hypertensive Drugs Market 2020-2025. Key players in the Global Anti-Hypertensive Drugs Market have been identified through the secondary research and their market share has been determined through primary and secondary research.

Global Anti-Hypertensive Drugs Market overview:

Antihypertensives are a class of drugs that are used to treat hypertension. Antihypertensive therapy seeks to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Evidence suggests that reduction of the blood pressure by 5 mmHg can decrease the risk of stroke by 34%, of ischaemic heart disease by 21% and reduce the likelihood of dementia, heart failure and mortality from cardiovascular disease. There are many classes of antihypertensives, which lower blood pressure by different means. Among the most important and most widely used medications are thiazide diuretics, calcium channel blockers, ACE inhibitors, angiotensin II receptor antagonists (ARBs) and beta blockers. The Global Anti-Hypertensive Drugs Market is segmented on the basis of Product Type, Application, End Use Industry and Region. This report also covers all the regions and countries of the world, which shows a regional development status, including market size. the growth rate of global economy will show a decrease of about 4%, due to this reason, Anti-Hypertensive Drugs market size in 2020.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/279508 .

On the Basis of Product Type segment, the Anti-Hypertensive Drugs Market is sub segmented into Diuretics, Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), Calcium Channel Blockers and Beta Blockers/Alpha Blockers/Vasodilators/Renin Inhibitors. Based on End Use Industry segment, the Anti-Hypertensive Drugs Market is segmented as Hospital Pharmacies,
Retail Pharmacies and Online Pharmacies.

There are several manufacturers of Anti-Hypertensive Drugs in Europe and North America. In North America, the demand for Anti-Hypertensive Drugs is primarily driven by the Healthcare sector. Among the countries in Asia Pacific, the demand was substantially high in developing countries such as China and India.

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Anti-Hypertensive Drugs Market Report 2020” @ https://www.businessindustryreports.com/buy-now/279508/single .

Top Industry News:

Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS) on 06 November, 2020 -- Novartis today announced new data from an interim analysis for the randomized, double-blind, placebo-controlled CAN-COVID trial evaluating the efficacy and safety of canakinumab in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS). The ongoing trial failed to meet its primary endpoint showing that treatment with canakinumab plus standard of care (SoC) did not demonstrate a significantly greater chance of survival for patients without the need for invasive mechanical ventilation, compared with placebo plus SoC up to Day 29. The trial did not meet its key secondary endpoint of reducing the COVID-19-related death rate during the 4-week period after treatment. The safety profiles of canakinumab plus SoC and placebo plus SoC were comparable.

“Though the CAN-COVID trial did not show the patient benefit we were hoping for, it helps improve the scientific understanding of COVID-19 and the role of interleukin-1β inhibition,” said John Tsai, M.D., Head of Global Drug Development and Chief Medical Officer for Novartis. “There’s still an urgent need for effective ways to combat COVID-19 and we will continue to apply our best scientific minds in support of the global pandemic response, including a Phase III trial of ruxolitinib. We’re deeply grateful to the patients who participated and their caregivers, as well as the healthcare professionals and hospital staff who made this research possible while fighting the pandemic on the front line.”

In the trial, the primary endpoint of survival without the need for mechanical ventilation was 88.8% for canakinumab plus SoC vs 85.7% for placebo plus SoC (P=0.29). The key secondary endpoint of COVID-19-related mortality up to 4 weeks was 4.9% for canakinumab plus SoC vs 7.2% for placebo plus SoC (P=0.33). Both the primary and key secondary endpoints trended in favor of canakinumab but did not reach statistical significance1. No new safety signals for canakinumab were identified.

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/279508 .

Major Key Players:

Some of the Anti-Hypertensive Drugs Market manufacturers involved in the market are Novartis, Pfizer, Johnson & Johnson, Sanofi, Lupin, Ranbaxy Laboratories, Merck, AstraZeneca, Daiichi Sankyo Company Limited, Takeda Pharmaceutical in World, effective mergers are some of the strategies adopted by the Anti-Hypertensive Drugs Market manufacturers. New product launches and continuous technological innovations are the Anti-Hypertensive Drugs Market strategies adopted by the major players.

Table of Contents:

1 Anti-Hypertensive Drugs Product Definition
2 Global Anti-Hypertensive Drugs Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Anti-Hypertensive Drugs Shipments
2.2 Global Manufacturer Anti-Hypertensive Drugs Business Revenue
2.3 Global Anti-Hypertensive Drugs Market Overview
2.4 COVID-19 Impact on Anti-Hypertensive Drugs Industry
3 Manufacturer Anti-Hypertensive Drugs Business Introduction
3.1 Novartis Anti-Hypertensive Drugs Business Introduction
3.1.1 Novartis Anti-Hypertensive Drugs Shipments, Price, Revenue and Gross profit 2015-2020
3.1.2 Novartis Anti-Hypertensive Drugs Business Distribution by Region
3.1.3 Novartis Interview Record
3.1.4 Novartis Anti-Hypertensive Drugs Business Profile
3.1.5 Novartis Anti-Hypertensive Drugs Product Specification
3.2 Pfizer Anti-Hypertensive Drugs Business Introduction
3.2.1 Pfizer Anti-Hypertensive Drugs Shipments, Price, Revenue and Gross profit 2015-2020
3.2.2 Pfizer Anti-Hypertensive Drugs Business Distribution by Region
3.2.3 Interview Record
3.2.4 Pfizer Anti-Hypertensive Drugs Business Overview
3.2.5 Pfizer Anti-Hypertensive Drugs Product Specification
3.3 Johnson & Johnson Anti-Hypertensive Drugs Business Introduction
3.3.1 Johnson & Johnson Anti-Hypertensive Drugs Shipments, Price, Revenue and Gross profit 2015-2020
3.3.2 Johnson & Johnson Anti-Hypertensive Drugs Business Distribution by Region
3.3.3 Interview Record
3.3.4 Johnson & Johnson Anti-Hypertensive Drugs Business Overview
3.3.5 Johnson & Johnson Anti-Hypertensive Drugs Product Specification
3.4 Sanofi Anti-Hypertensive Drugs Business Introduction
3.5 Lupin Anti-Hypertensive Drugs Business Introduction
3.6 Ranbaxy Laboratories Anti-Hypertensive Drugs Business Introduction
……

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.